Filana Therapeutics, Inc. (FLNA) - Total Liabilities
Based on the latest financial reports, Filana Therapeutics, Inc. (FLNA) has total liabilities worth $40.29 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Filana Therapeutics, Inc. (FLNA) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Filana Therapeutics, Inc. - Total Liabilities Trend (2022–2025)
This chart illustrates how Filana Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see FLNA total asset value.
Filana Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Filana Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
US Energy Corp
NASDAQ:USEG
|
USA | $21.46 Million |
|
Corentec Co Ltd
KQ:104540
|
Korea | ₩90.03 Billion |
|
Verusaturk Girisim Sermayesi
IS:VERTU
|
Turkey | TL10.84 Million |
|
Culp, Inc. Common Stock
NYSE:CULP
|
USA | $70.53 Million |
|
Star Equity Holdings Inc
NASDAQ:STRR
|
USA | $47.52 Million |
|
Minesto AB
ST:MINEST
|
Sweden | Skr22.24 Million |
|
Adcorp
JSE:ADR
|
South Africa | ZAC1.69 Billion |
|
Samwha Elec
KO:011230
|
Korea | ₩56.82 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Filana Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Filana Therapeutics, Inc. (FLNA) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Filana Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Filana Therapeutics, Inc. (2022–2025)
The table below shows the annual total liabilities of Filana Therapeutics, Inc. from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $43.95 Million | +271.56% |
| 2024-12-31 | $11.83 Million | -16.67% |
| 2023-12-31 | $14.20 Million | +94.59% |
| 2022-12-31 | $7.29 Million | -- |
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from… Read more